Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) stock analysis
REGN · Regeneron Pharmaceuticals, Inc. - Common Stock
Latest recorded price: USD 952.40
Model-estimated fair value: USD 623.40. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $952.40, REGN trades 52.8% above the model's base-case value of $623.40. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $506.93 in the conservative case and $752.10 in the optimistic case, with a valuation confidence score of 55/100. About 72% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 5.6%, free cash flow margin 28.4%, ROIC 11.8%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Relay Therapeutics, Inc. (RLAY)
- Roivant Sciences Ltd. (ROIV)
- Royalty Pharma plc (RPRX)
- Revolution Medicines, Inc. (RVMD)
- Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
- Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
- SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
- Summit Therapeutics Inc. (SMMT)